
Patient Blood Management: Treating Anemia

Yulia Lin, MD, FRCPC, CTBS Division Head, Transfusion Medicine, Sunnybrook HSC Associate Professor, Dept of Laboratory Medicine and Pathobiology, University of Toronto Transfusion Camp Day 4, March 26, 2021







Quality Utilization Efficacy Safety Transfusion



Disclosures


• No conflicts of interest

Objectives

- 1. Advocate for the importance of patient blood management
- 2. Diagnose and treat iron deficiency anemia
- 3. Decide which patients should receive preoperative erythropoietin

Patient Blood Management


 PBM is an evidence-based, multidisciplinary approach to optimizing care of patients who might need transfusion



http://www.aabb.org/pbm/Pages/default.aspx

Patient Blood Management

 PBM is an evidence-based, multidisciplinary approach to optimizing care of patients who might need transfusion



http://www.aabb.org/pbm/Pages/default.aspx

Why is treating preoperative anemia so important?

#1 Preoperative anemia is associated with increased mortality 2018 PBM Consensus Conference OR 2.09 (95%Cl, 1.48-2.95) 2014 Europe N= 39,309 pts OR 1.99 (95%Cl, 1.67-2.37) 2011 US NSQIP N= 227, 425 pts OR 1.42 (95% Cl, 1.31-1.54)

Mueller et al. JAMA 2019;321(10):983-97; Baron et al. BJA 2014;113:416-23; Mussallam et al. Lancet 2011;378:1396-1407

#2 Preoperative anemia is potentially modifiable





Figure 1: 30-day mortality, by anaemia and risk factor status COPD--chronic obstructive pulmonary disease.

Mussallam et al. Lancet 2011;378:1396-1407

#3 Preoperative anemia is common (25-40%)!




Anemia in 36% (1/3)

Hb ≥ 130 g/L
Hb 100-129 g/L
Hb < 100 g/L


Fowler et al. BJS 2015;102:1314-24. Baron. BJA 2014; Musallam. Lancet 2011; Munoz et al. Anaesthesia 2017;72:826-34

#4 Pre-op anemia associated with \uparrow transfusion





Freedman et al. Transfusion 2008;48:237-50



Carson et al. Am Heart Journal 2018;200:96-101

NSQIP Studies of Perioperative Transfusion

Study	Surgery type	# pts	Outcome	Assoc w/ transfusion
Halabi 2010	Colorectal cancer resection	27 120	30-day mortality	OR 1.78
O'Keeffe 2010	Lower extremity revascularization	8 799	30-day mortality	OR 1.92
de la Fuente 2011	Pancreatico-duodenectomy	6 293	30-day mortality	OR 1.91
Tzeng 2013	Hepatectomy in elderly	7 621	30-day mortality	OR 2.37
Pugeley 2013	Lumbar discectomy	4 310	Any complication	OR 1.54
Fischer 2014	Breast reconstruction	16 063	Major surgical complications	OR 2.9
Hart 2015	Total knee arthroplasty	13 662	30-day mortality	OR 2.7
Prescott 2015	Gynecologic cancer surgery	8 519	30-day mortality	OR 3.38

Courtesy of J. Pendergrast, Transfusion Camp Day 4. March 2018.

Advocate for PBM because...

- 1. Preoperative anemia is bad
- 2. Preoperative anemia is modifiable
- 3. Preoperative anemia is common
- 4. Transfusion is a bad outcome
- 5. The donor supply is a precious resource

What are strategies to treat anemia and prevent transfusion?

Poll Question

- Which of the following interventions have you prescribed before?
 - Autologous blood
 - Oral iron
 - Intravenous iron
 - Epoetin alfa or darbepoetin

Quick point: Autologous blood donation is to be considered only in rare circumstances!

What is Autologous Donation?

- Patient donates own blood before surgery with sufficient time to allow patient to make up loss
- Goal: to provide <u>additional</u> RBC units for surgery (个 red cell mass)





Pitfalls of Autologous Donation

- Takes at least 4 wks to re-generate autologous blood
- Preop Hb was 11 g/L lower in autologous group (systematic review 14 RCTs)
- More expensive due to 50% wastage rate
 - 1 allogeneic unit costs \$422 (CBS 2018-19)

Henry DA et al. Cochrane Database Syst Rev 2001;(4):CD003602. Update Apr 2010

Current state in 2021

• Preop autologous blood donation NOT recommended

- Exceptions
 - Patients with <u>very</u> rare blood type not easily met by donor base (e.g. unusual or multiple antibodies)
 - Contact the transfusion service in these cases!

Objective #2: Diagnose and Treat Iron Deficiency Anemia (early)

What is Preop Anemia?


- WHO: Hb < 130 g/L males; Hb < 120 g/L females
- NEW: Hb < 130 g/L used for all (high blood loss surgery)
 - Both sexes lose same amount of blood
 - Women have lower circulating blood volume
 - Accepting lower preop Hb for women 个transfusion risk
 - NSQIP data: risk increases as hemoglobin levels < 130 g/L with no sex differential

Detection


- Who should be screened?
 - All high blood loss surgery (> 500 mL): ortho, cardiac, cancer
 - All high risk for severe anemia: colorectal, gyne
- When?
 - 4-8 weeks before surgery
- How?
 - CBC, ferritin, TSAT, B12, creatinine
 - Focus on iron deficiency anemia (common & treatable)

How to diagnose IDA?


• Ferritin




- Reflection of iron stores
- Ferritin < 30 ug/L = Iron deficiency</p>
- Serum Fe 🗧
- Transferrin (TIBC)
 - Transport protein of Fe
- Transferrin saturation
 - Serum Fe / TIBC








Iron Pathway



Andrews. Blood 2008;112:219

Anemia of Chronic Disease – Hepcidin




Andrews. Blood 2008;112:219

Defining iron deficiency anemia

Absolute Iron Deficiency: Ferritin < 30 mcg/L; or Ferritin < 100 + TSAT < 20% ± CRP > 5 mg/L

Low iron stores: Ferritin 30-100 mcg/L + TSAT > 20%

Munoz et al. International Consensus. Anaesthesia 2017;72:233-47 Kotze et al. BCSH guidelines . BJH 2015;17-322-31; Goodnough et al. NATA guidelines. BJA 2011;106:13-22



Munoz et al. Anaesthesia 2017;72:826-34

Table 1. Causes of iron-deficiency anemia in the preoperative setting

Causes of preoperative iron-deficiency anemia

Too much iron OUT

Increased loss

- Blood loss, eg, gastrointestinal, gynecological bleeding
- Blood donation
- Increased requirements
 - Rapid growth in infants and children
 - Pregnancy
 - Use of ESAs

Too little iron IN

Decreased iron intake

- Iron-poor diet
- · Vegetarian or vegan

Decreased absorption

- Celiac disease
- · Gastrectomy, gastric bypass, gut resection
- Helicobacter pylori
- Inflammatory bowel disease
- Drugs: antacids, proton pump inhibitors
- Foods: calcium, tannins (tea, coffee), phytates

GI lesions in IDA: Colon 5-10% Upper GI 1-5%

Case: Vegan x 10 yrs OGD, C-scope N Chronic anemia HTN > Kidney

Oral Iron



- Small studies: no difference (RCT) to small *†Hb, transfusion rate* (observational)
- Greater benefit if given for
 - Longer course (> 14 days vs. < 14 days)
 - Patients with anemia (vs. no anemia)



Okuyama et al. Surg Today 2005;35:36-40; Lidder et al. Ann R Coll Surg Engl 2007;89:418-21 Quinn et al. Ann R Coll Surg Engl 2010; 92:569-72; Parker et al. J Bone Joint Surg Am 2010 Feb;92(2):265-9



Oral Iron Salts

	Dose mg	Elemental mg	Cost
Ferrous gluconate (ODB)	300	35	\$0.13
Ferrous sulfate	300	60	\$0.03
Ferrous fumarate (ODB)	300	100	\$0.13-0.43

- Inexpensive (over the counter)
- Take on an empty stomach
- Absorption only 10% of elemental Fe
- GI side effects: epigastric pain, heartburn, nausea, vomiting, constipation or diarrhea
 Sunnybroc

Sunnybrook Pharmacy 2020

Oral Iron




	Dose	Elemental mg	Cost
	mg		
Polysaccharide (Triferex)	150	150	\$0.71
Polysaccharide (Feramax)	150	150	\$0.92
Heme iron (Proferrin)	398	11	\$1.03

- Fewer side effects
- More expensive
- No evidence that more effective than oral iron salts

Sunnybrook Pharmacy 2020





2017 ONTraC data: Hb change 1 g/L vs. 13 g/L (p<0.0001) Lead time < 3 weeks in ~50%

Lin et al. CSTM Conference Abstract 2019


Oral vs. IV iron

• Oral iron: response in 3-4 weeks; 5-10g/L per week

- Indications for IV iron
 - Oral iron not tolerated or effective
 - Short time to surgery < 4-6 weeks
 - Severe anemia, e.g. Hb < 100 g/L</p>
 - Active bleeding

Preoperative IV iron

- \uparrow Hb in 11 of 17 studies (+/- ESA*)
- \downarrow transfusion in 8 of 13 studies



Peters F et al. Anesth Analg 2018;126:1268-82


RCT: IV Iron in Abdo Surgery

- 72 pts for major abdominal surgery
 - Average Hb 107 g/L; Ferritin < 300, TSAT < 25% (mean ferritin 19-37)
- Randomized to IV iron or usual care
 - Ferric carboxymaltose 15mg/kg up to 1000mg preop + postoperative
 0.5 mg per mL blood loss
 - Usual care: nothing
 - Only 3 patients prescribed oral iron in entire cohort
 - IV iron: 1 pt preop and 4 pts post-op

RCT: IV Iron in Abdo Surgery

- Terminated early due to poor outcomes in usual care group! (target 268 pts)
 - \uparrow Hb increment 8 g/L vs. 1 g/L pre-op (p=0.01)
 - ↓ transfusion 12.5% vs. 31.3% (p<0.0003)</p>
 - $-\downarrow$ length of stay 7.0 vs 9.7 days (p=0.026)
 - ↑ Hb at 4 wks 122 g/L vs. 111 g/L (p<0.001)</p>
- *"Usual care failed the majority of participating patients, leaving them untreated with a treatable condition"*

PREVENTT Trial



Blood Transfusion/Death: 28% vs. 29% (RR 1.03; 95% CI 0.78-1.37)

Number of transfusions: 111 vs. 105 (RR 0.98; 95% CI 0.68-1.43)

Richards et al. Lancet 2020

PREVENTT Trial

- Mean baseline Hb 111 g/L with Hb above 100 g/L in 83%
- No baseline iron criteria; 5% had IBD; 29% had iron deficiency
- Intervention:
 - Median 15 days preop; Hb 个 5 g/L preop
 - Anemia corrected 21% vs. 10%
 - No specific transfusion protocol
- No difference in subgroups (Hb <> 100; ferritin <>100)
- No difference in postop complications, LOS, QOL
- Decreased risk of readmission to hospital in IV iron group

Richards et al. Lancet 2020


Intravenous iron	iron sucrose	ferric gluconate	iron isomaltoside	
Name	Venofer	Ferrlcit	Monoferric	
Indication	IDA in CKD	IDA in HD epo	IDA no oral iron cannot be used	
MW (kDa)	43	289-440	150	
Max single dose	300mg	125 mg	1500 mg	
Test dose	No	No	No	
Infusion time	2 hours	1 hour	60 minutes (1000mg)	
Cost (ONT wholesale)	\$39.56 (100mg)	\$44.50 (100mg)	\$48.60 (100mg)	
Life threatening ADE	0.6 per 10 ⁶	0.9 per 10 ⁶	comparable	

Munoz et al. Blood Transfus 2012;10:8-22; Chertow et al. Nephrol Dial Transpl 2006;21:378-82; Wang et al. JAMA 2015;314:2062-68

How to give it

- What dose?
 - Ganzoni formula
 - Dose = [wt (kg) x (target initial Hb g/dL) x 2.4] + 500mg
 - In practice, 1000 1500 mg
- Adverse effects: rare anaphylactic (24 per 100,000 US data), hypotension, muscle cramps, arthralgias, back pain, headache

Hypersensitivity reactions



• Transfer to ED/acute care or monitored setting Lim et al. Vox Sang 2019;114:363-73 Objective #3: Consider the role of Erythropoiesis-stimulating agents

Study		%	
ID	RR (95% CI)	Weight	
Aydin 2012	0.78 (0.46, 1.33)	4.20	
Christodoulakis 2005	0.83 (0.61, 1.12)	5.06	
D'Ambra 1997	0.63 (0.43, 0.91)	4.78	
Dardashti 2014	1.38 (0.88, 2.14)	4.55	
deAndrade 1996	0.46 (0.28, 0.78)	4.23	
Dousias 2003	0.11 (0.01, 1.82)	0.52	Preop EPO in
Dousias 2005	0.13 (0.01, 2.34)	0.51	
Faris 1996	0.39 (0.26, 0.60)	4.66	Surgical Pts
Feagan 2000	0.42 (0.27, 0.65)	4.54	Juigicai i ts
Gaston 2006	1.00 (0.07, 15.12)	0.57	
Haljan 2009	0.17 (0.02, 1.60)	0.79	32 trials
Heiss 1996	1.32 (0.55, 3.20)	2.90	
Kettelhack 1998	1.20 (0.67, 2.16)	3.97	4,750 pts
Kim 2013	1.05 (0.66, 1.68)	4.45	
Kosmadakis 2003	0.37 (0.22, 0.62)	4.21	
Luchette 2012	1.22 (0.88, 1.70)	4.97	
Na 2011	0.38 (0.21, 0.68)	3.99	Decreaced
Norager 2006	1.13 (0.49, 2.61)	3.03	Decreased
Podesta 2000	0.04 (0.01, 0.27)	1.02	
Qvist 1999	0.64 (0.38, 1.08)	4.23	transfusion
Scott 2022	0.79 (0.58, 1.08)	5.03	
Sowade 1997	0.21 (0.08, 0.56)	2.62	OR 0.59
Tsuji 1995	- 0.33 (0.02, 6.65)	0.48	011 0.55
Weber 2005	0.24 (0.17, 0.34)	4.95	(0.47, 0.73)
Weltert 2010	0.43 (0.28, 0.64)	4.66	(0.47, 0.75)
Weltert 2015	0.44 (0.33, 0.58)	5.11	
Wurnig 2001	0.60 (0.42, 0.86)	4.88	
Yoo 2011	0.69 (0.51, 0.92)	5.08	
Overall (I-squared = 79.0%, p = 0.000)	0.59 (0.47, 0.73)	100.00	
NOTE: Weights are from random effects analysis			
.00557 Favors EPO 1 Fa	avors Placebo 1 180		

Figure 2. The weighted (pooled) estimate for the effect of preoperative erythropoietin (EPO) administration on incidence of whole hospitalization allogeneic transfusions (risk ratio [RR], 0.59; 95% CI, 0.47–0.73; P < .001) compared to placebo administration.

Cho et al. Anesth Analg 2019; 128:981-992

Concerns about ESA

- Chronic kidney disease
 - CHOIR: Epo to \uparrow Hb to 135 g/L (vs. 113 g/L) associated with \uparrow arterial TE events
 - CREATE: Epo to ↑ Hb to 130-150 g/L (vs. 105-115 g/L) no difference
 - TREAT: Darbepoietin to 个 Hb to 130 g/L (vs. placebo) no difference in composite outcome, but 个 stroke in darbepoietin group
 - ESA used for > 16 months

Singh et al. NEJM 2006;355:2085-98 Druecke et al. NEJM 2006;255:2071-84 Pfeffer et al. NEJM 2009;361:2019-32




Figure 3. The weighted (pooled) estimate for effect of preoperative erythropoietin (EPO) administration on incidence of thromboembolic events (risk ratio [RR], 1.02; 95% CI, 0.78-1.33; P = .68) compared to placebo administration.

Concerns about ESA

- Cancer
 - Concern about tumour progression
 - Not clear how as tumours have low/undetectable EpoR
 - Restricted to certain tumour types (e.g. H&N XRT)
 - Controversial whether there is \uparrow mortality RR 0.97 1.17 (2 SR \uparrow , 3 SR no difference)
 - How? VTE related? Poor responders to ESAs?
 - ESA use > 8 weeks

Bohlius 2006; Bennett 2008; Ludwig 2009; Tonelli 2009; Aapro 2009; Glaspy 2010 http://www.fda.gov/cder/drug/infopage/RHE/qa2007.html

The role of ESAs

Guidelines: role of preop ESAs less clear

- 1. High blood loss surgery (> 10% transfusion)
 - cardiac, orthopedic, major abdominal surgery
- 2. Patients with anemia: Hb < 12-13 g/dL
 - Religious objections to blood transfusion
 - Multiple alloantibodies \rightarrow difficult to find blood

Goodnough et al. NATA guidelines 2011; NICE guidelines 2015; Kozek-Langenecker et al. Eur J Anaesth 2017;34:332-95

Even if there is not much time...

- Ultra-short anemia treatment
 - 484 pts elective cardiac surgery, anemia, ferritin < 100
 - Day before surgery: iv iron 20mg/kg, epo 40,000 units, B12, folic acid (vs. placebo)
 - ↓ RBC units in 7d (median 0 vs. 1; OR 0.7 (95% CI 0.50-0.98))
 - No difference in clinical outcomes, TE, safety

Practical Aspects

• Requires adequate lead time (3-4 weeks)


short term use

- Dose: 40,000 units s.c. q weekly x 2-4 doses 🥌
- Side effects: flu like symptoms with bone/muscle pain, hypertension (typically with longer term use)
- Iron supplementation
- Cost effectiveness uncertain
- Postop DVT prophylaxis

Obstetrics - Screen for Anemia

- ACOG
 - All pregnant women should be screened for anemia
 - Treat with iron if iron deficient
- BCH
 - Full blood count at booking (1st trimester) and at 28 wks
 - Anemic women with no other obvious cause: diagnostic trial of oral iron with CBC repeat at 2-3 wks


QI Project – IRON MOM Canada




Outcomes: ↑ ferritin tests ↓ anemia at delivery (13.5% to 10.6%, p>0.001) ↓ transfusions (1.2% vs. 0.8%, p=0.049)

Guideline for Iron Deficiency Anemia Management in the ED

Note: Please refer to WebER for patient pamphlet, IV iron orders (written consent not required), oral iron prescription and discharge letter.



Emergency Dept - Appropriate transfusion for IDA




- A. IV iron avail. in ED
- B. IV iron guideline
- C. Stakeholder feedback
- D. Grand rounds
- E. Access to TM MD
- F. Podcast release
- G. ED IDA toolkit

Khadadah, Lin et al. Transfusion 2018;58:1902-8

Summary – Treat anemia

- Preoperative anemia & transfusion are associated with bad perioperative outcomes
- Look for treatable anemia (Do CBC EARLY!)
- Look for iron deficiency anemia (common)
 - Ferritin < 30 ug/L; Ferritin < 100 ug/L + TSAT<20%</p>
 - Make sure the underlying cause is identified in IDA
- Consider preop erythropoietin in high blood loss surgery especially in pts with religious objections or rare blood needs



Lin Y. ASH Education Book. Hematology 2019

